Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort

Prostate

Volumn 76, Issue 15, 2016, Pages 1409-1419

  Brooks, James D ^a   Wei, Wei ^b   Pollack, Jonathan R ^c   West, Robert B ^c   Shin, Jun Ho ^a   Sunwoo, John B ^a   Hawley, Sarah J ^a   Auman, Heidi ^a   Newcomb, Lisa F ^d   Simko, Jeff ^e   Hurtado Coll, Antonio ^f   Troyer, Dean A ^g,h   Carroll, Peter R ⁱ   Gleave, Martin E ^f   Lin, Daniel W ^d   Nelson, Peter S ^j   Thompson, Ian M ^g   True, Lawrence D ^d   McKenney, Jesse K ^k   Feng, Ziding ^b   Fazli, Ladan ^f   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VANCOUVER PROSTATE CENTRE   (Canada)

^g University of Texas Health Science Center   (United States)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

AZGP1; immunohistochemistry; prognosis; prostate cancer

Indexed keywords

ALPHA 2 GLYCOPROTEIN 1 ZINC BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ZINC BINDING PROTEIN; AZGP1 PROTEIN, HUMAN; CARRIER PROTEIN; GLYCOPROTEIN; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RNA IN SITU HYBRIDIZATION; SEMINAL VESICLE; TISSUE MICROARRAY; BIOSYNTHESIS; CASE CONTROL STUDY; CLINICAL TRIAL; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VALIDATION STUDY;

BIOMARKERS, TUMOR; CARRIER PROTEINS; CASE-CONTROL STUDIES; GLYCOPROTEINS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84977579701     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23225     Document Type: Article

References (37)

1. USPSTF. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2008; 149(3):185–191.
2. Saquib N, Saquib J, Ioannidis JP. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. Int J Epidemiol 2015; 44(1):264–277.
3. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360(13):1310–1319.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366(11):981–990.
5. Brooks JD. Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer 2013; 119(22):3906–3909.
6. Carter HB. Active surveillance for favorable risk prostate cancer. Curr Opin Urol 2015; 25(3):230–231.
7. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Onc 2015; 33(3):272–277.
8. Newcomb LF, Thompson IM Jr., Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW, Canary PI. Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional canary PASS cohort. J Urol 2016; 195(2):313–320.
9. Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI, Trock BJ, Macura KJ. Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: A preliminary report on disease outcomes. Urology 2015; 85(1):147–153.
10. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: Design of a multi-institutional active surveillance cohort and biorepository. Urology 2010; 75(2):407–413.
11. Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C, Raskolnikov D, Su D, Shih J, Han H, Parnes HL, Merino MJ, Simon RM, Wood BJ, Choyke PL, Pinto PA. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol 2015; 33(5):202, e201–e207.
12. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: The Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol 2013; 20(1):39–44.
13. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK. Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients. PLoS ONE 2015; 10(7):e0132343.
14. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate 2015; 75(11):1206–1215.
15. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101(3):811–816.
16. Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006; 66(10):1037–1043.
17. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. JNCI 2006; 98(19):1420–1424.
18. Mills J, Oliver A, Sherwin JC, Frydenberg M, Peters JS, Costello A, Harewood L, Love C, Redgrave N, van Golen KL, Bailey M, Pedersen J. Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer. Pathology 2012; 44(6):513–518.
19. Severi G, FitzGerald LM, Muller DC, Pedersen J, Longano A, Southey MC, Hopper JL, English DR, Giles GG, Mills J. A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease. Cancer Med 2014; 3(5):1266–1274.
20. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014; 66(3):550–560.
21. Brooks JD. Translational genomics: The challenge of developing cancer biomarkers. Genome Res 2012; 22(2):183–187.
22. Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. PTEN loss by clinical-grade immunohistochemistry assay is associated with worse recurrence free survival in prostate cancer. Eur Urol Focus 2016; 2(2):180–188.
23. Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley ST, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer D, Hurtado-Coll A, Thompson IM, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD. Prognostic value of Ki67 in localized prostate carcinoma: A multi-institutional study of >1,000 prostatectomies. Prostate Cancer Prostate Dis 2016; in press.
24. Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. Int J Cancer 2016; 138(5):1199–1206.
25. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1(2):203–209.
26. Yip PY, Kench JG, Rasiah KK, Benito RP, Lee CS, Stricker PD, Henshall SM, Sutherland RL, Horvath LG. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011; 71(15):1638–1645.
27. Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC. Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer. PLoS ONE 2013; 8(7):e69155.
28. Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Translat Med 2012; 10:106.
29. Parris TZ, Kovacs A, Aziz L, Hajizadeh S, Nemes S, Semaan M, Forssell-Aronsson E, Karlsson P, Helou K. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. Int J Cancer 2014; 134(7):1617–1629.
30. Bohm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene 2009; 28(43):3847–3856.
31. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, Brooks JD. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 2005; 63(2):187–197.
32. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 2002; 3(7):RESEARCH0032.
33. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99(18):11890–11895.
34. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Zinc alpha 2-glycoprotein: A multidisciplinary protein. Mol Cancer Res 2008; 6(6):892–906.
35. Sanchez LM, Lopez-Otin C, Bjorkman PJ. Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc Natl Acad Sci USA 1997; 94(9):4626–4630.
36. Chang L, Tian X, Lu Y, Jia M, Wu P, Huang P. Alpha-2-glycoprotein 1(AZGP1) regulates biological behaviors of LoVo cells by down-regulating mTOR signaling pathway and endogenous fatty acid synthesis. PLoS ONE 2014; 9(6):e99254.
37. Kong B, Michalski CW, Hong X, Valkovskaya N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H, Kleeff J. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-beta-mediated ERK signaling. Oncogene 2010; 29(37):5146–5158.